You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMycophenolic acid
Accession NumberDB01024  (APRD01603, EXPT02208)
TypeSmall Molecule
GroupsApproved
DescriptionMycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase).
Structure
Thumb
Synonyms
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Micofenolico acido
Mycophenolate
Mycophenolsäure
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Myfortictablet (enteric-coated)180 mgoralNovartis Pharmaceuticals Canada Inc2005-02-11Not applicableCanada
Myfortictablet, delayed release180 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Myfortictablet (enteric-coated)360 mgoralNovartis Pharmaceuticals Canada Inc2005-02-11Not applicableCanada
Myfortictablet, delayed release180 mg/1oralNovartis Pharmaceuticals Corporation2004-02-27Not applicableUs
Myfortictablet, delayed release360 mg/1oralNovartis Pharmaceuticals Corporation2004-02-27Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mycophenolic Acidtablet (enteric-coated)180 mgoralApotex Inc2014-07-02Not applicableCanada
Apo-mycophenolic Acidtablet (enteric-coated)360 mgoralApotex Inc2014-07-02Not applicableCanada
Mycophenolic Acidtablet, delayed release360 mg/1oralGolden State Medical Supply, Inc.2014-10-13Not applicableUs
Mycophenolic Acidtablet, delayed release180 mg/1oralMylan Pharmaceuticals Inc.2014-01-08Not applicableUs
Mycophenolic Acidtablet, delayed release360 mg/1oralAmerican Health Packaging2015-01-15Not applicableUs
Mycophenolic Acidtablet, delayed release180 mg/1oralApotex Corp2012-08-21Not applicableUs
Mycophenolic Acidtablet, delayed release360 mg/1oralMylan Pharmaceuticals Inc.2014-01-08Not applicableUs
Mycophenolic Acidtablet, delayed release360 mg/1oralApotex Corp2014-08-19Not applicableUs
Mycophenolic Acidtablet, delayed release180 mg/1oralMylan Institutional Inc.2014-02-11Not applicableUs
Mycophenolic Acidtablet, delayed release180 mg/1oralGolden State Medical Supply, Inc.2014-10-13Not applicableUs
Mycophenolic Acidtablet, delayed release180 mg/1oralAmerican Health Packaging2015-01-15Not applicableUs
Mycophenolic Acidtablet, delayed release360 mg/1oralMylan Institutional Inc.2014-02-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MelbexNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mycophenolate sodium
ThumbNot applicableDBSALT001740
Categories
UNIIHU9DX48N0T
CAS number24280-93-1
WeightAverage: 320.3371
Monoisotopic: 320.125988372
Chemical FormulaC17H20O6
InChI KeyInChIKey=HPNSFSBZBAHARI-RUDMXATFSA-N
InChI
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
IUPAC Name
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
SMILES
COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsobenzofurans
Sub ClassIsobenzofuranones
Direct ParentPhthalides
Alternative Parents
Substituents
  • Phthalide
  • Methoxyphenol
  • Medium-chain fatty acid
  • Anisole
  • Methyl-branched fatty acid
  • Heterocyclic fatty acid
  • Branched fatty acid
  • Alkyl aryl ether
  • Fatty acyl
  • Fatty acid
  • Benzenoid
  • Unsaturated fatty acid
  • Dicarboxylic acid or derivatives
  • Vinylogous acid
  • Lactone
  • Carboxylic acid ester
  • Oxacycle
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.
PharmacodynamicsMycophenolic acid is an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.
Mechanism of actionMycophenolic acid is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, mycophenolic acid has potent cytostatic effects on lymphocytes. Mycophenolic acid inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of mycophenolic acid on lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes. Mycophenolic acid prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection.
Related Articles
AbsorptionBioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%
Volume of distribution
  • 54 ± 25 L
Protein binding>98%
Metabolism

Mycophenolic acid is metabolized mainly by glucuronyl transferase to glucuronidated metabolites, predominantly the phenolic glucuronide, mycophenolic acid glucuronide (MPAG). MPAG does not manifest pharmacological activity. The acyl glucuronide minor metabolite has pharmacological activity similar to mycophenolic acid. The AUC ratio of Mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state.

SubstrateEnzymesProduct
Mycophenolic acid
Mycophenolic acid-acyl glucuronideDetails
Mycophenolic acid
6-O-desmethyl-mycophenolic acidDetails
Mycophenolic acid
Mycophenolic acid-7-O-glucuornideDetails
Route of eliminationNot Available
Half lifeThe mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.
Clearance
  • 140 +/- 30 mL/min [Stable renal transplant patients]
ToxicityOral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mycophenolic Acid Metabolism PathwayDrug metabolismSMP00652
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9409
Blood Brain Barrier+0.5826
Caco-2 permeable-0.5583
P-glycoprotein substrateSubstrate0.8058
P-glycoprotein inhibitor INon-inhibitor0.7888
P-glycoprotein inhibitor IIInhibitor0.545
Renal organic cation transporterNon-inhibitor0.8199
CYP450 2C9 substrateNon-substrate0.8305
CYP450 2D6 substrateNon-substrate0.8575
CYP450 3A4 substrateSubstrate0.6934
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7237
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9619
BiodegradationReady biodegradable0.5888
Rat acute toxicity2.9907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.753
hERG inhibition (predictor II)Non-inhibitor0.6329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, delayed releaseoral180 mg/1
Tablet, delayed releaseoral360 mg/1
Tablet (enteric-coated)oral180 mg
Tablet (enteric-coated)oral360 mg
Prices
Unit descriptionCostUnit
Myfortic 360 mg Enteric Coated Tabs8.0USD tab
Myfortic 360 mg tablet7.69USD tablet
Myfortic 180 mg tablet3.85USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2250906 No2006-10-032017-04-10Canada
US6025391 No1997-04-102017-04-10Us
US6172107 No1997-04-102017-04-10Us
US6306900 No1998-02-272018-02-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point141 °CPhysProp
water solubilityInsolubleNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0355 mg/mLALOGPS
logP2.36ALOGPS
logP3.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.57ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.23 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Bernard J. Abbott, John G. Whitney, “Method of preparing mycophenolic acid glucoside.” U.S. Patent US4234684, issued January, 1976.

US4234684
General References
  1. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [PubMed:15899149 ]
External Links
ATC CodesL04AA06
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelNot Available
MSDSDownload (74 KB)
Interactions
Drug Interactions
Drug
AbciximabMycophenolic acid may increase the anticoagulant activities of Abciximab.
AcebutololMycophenolic acid may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aceclofenac.
AcenocoumarolMycophenolic acid may increase the anticoagulant activities of Acenocoumarol.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mycophenolic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolic acid.
Alendronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.
AliskirenMycophenolic acid may decrease the antihypertensive activities of Aliskiren.
AlprenololMycophenolic acid may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolic acid.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmdinocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amdinocillin resulting in a loss in efficacy.
AmikacinMycophenolic acid may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMycophenolic acid may decrease the antihypertensive activities of Amiloride.
AmoxicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amoxicillin resulting in a loss in efficacy.
AmpicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ampicillin resulting in a loss in efficacy.
AncrodMycophenolic acid may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.
Antithrombin III humanMycophenolic acid may increase the anticoagulant activities of Antithrombin III human.
ApixabanMycophenolic acid may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apremilast.
ArdeparinMycophenolic acid may increase the anticoagulant activities of Ardeparin.
ArgatrobanMycophenolic acid may increase the anticoagulant activities of Argatroban.
ArotinololMycophenolic acid may decrease the antihypertensive activities of Arotinolol.
AtenololMycophenolic acid may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.
AzlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azlocillin resulting in a loss in efficacy.
BalsalazideMycophenolic acid may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Mycophenolic acid.
BecaplerminMycophenolic acid may increase the anticoagulant activities of Becaplermin.
BefunololMycophenolic acid may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolic acid.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolic acid.
BenoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benoxaprofen.
Benzathine benzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzathine benzylpenicillin resulting in a loss in efficacy.
BenzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicillin resulting in a loss in efficacy.
Benzylpenicillin PotassiumThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicillin Potassium resulting in a loss in efficacy.
BetaxololMycophenolic acid may decrease the antihypertensive activities of Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Mycophenolic acid.
BevantololMycophenolic acid may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolic acid.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololMycophenolic acid may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMycophenolic acid may increase the anticoagulant activities of Bivalirudin.
BopindololMycophenolic acid may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mycophenolic acid.
BufuralolMycophenolic acid may decrease the antihypertensive activities of Bufuralol.
BumetanideMycophenolic acid may decrease the diuretic activities of Bumetanide.
BupranololMycophenolic acid may decrease the antihypertensive activities of Bupranolol.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolic acid.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mycophenolic acid.
CarbenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carbenicillin resulting in a loss in efficacy.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolic acid.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Mycophenolic acid.
CarteololMycophenolic acid may decrease the antihypertensive activities of Carteolol.
CarvedilolMycophenolic acid may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mycophenolic acid.
CeliprololMycophenolic acid may decrease the antihypertensive activities of Celiprolol.
CertoparinMycophenolic acid may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolic acid.
CholestyramineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cholestyramine.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolic acid.
Citric AcidMycophenolic acid may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mycophenolic acid.
CloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cloxacillin resulting in a loss in efficacy.
ColesevelamThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colesevelam.
ColestipolThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colestipol.
CyclacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.
CyclosporineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.
CyclosporineMycophenolic acid may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with D-Limonene.
Dabigatran etexilateMycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinMycophenolic acid may increase the anticoagulant activities of Dalteparin.
DanaparoidMycophenolic acid may increase the anticoagulant activities of Danaparoid.
DaunorubicinMycophenolic acid may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deferasirox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.
DesirudinMycophenolic acid may increase the anticoagulant activities of Desirudin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mycophenolic acid.
DesmopressinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolic acid.
DextranMycophenolic acid may increase the anticoagulant activities of Dextran.
Dextran 40Mycophenolic acid may increase the anticoagulant activities of Dextran 40.
Dextran 70Mycophenolic acid may increase the anticoagulant activities of Dextran 70.
Dextran 75Mycophenolic acid may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolic acid.
DicloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Dicloxacillin resulting in a loss in efficacy.
DicoumarolMycophenolic acid may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mycophenolic acid.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mycophenolic acid.
DigoxinDigoxin may decrease the cardiotoxic activities of Mycophenolic acid.
DihydrostreptomycinMycophenolic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolic acid.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.
DoxorubicinMycophenolic acid may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneMycophenolic acid may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Droxicam.
Edetic AcidMycophenolic acid may increase the anticoagulant activities of Edetic Acid.
EdoxabanMycophenolic acid may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mycophenolic acid.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolic acid.
EnoxaparinMycophenolic acid may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Epirizole.
EpirubicinMycophenolic acid may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneMycophenolic acid may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.
EsmololMycophenolic acid may decrease the antihypertensive activities of Esmolol.
EsomeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Esomeprazole.
Etacrynic acidMycophenolic acid may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.
Ethyl biscoumacetateMycophenolic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Mycophenolic acid.
EtofenamateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolic acid.
FingolimodMycophenolic acid may increase the immunosuppressive activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolic acid.
FlucloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Flucloxacillin resulting in a loss in efficacy.
FlunixinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mycophenolic acid.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolic acid.
Fondaparinux sodiumMycophenolic acid may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolic acid.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolic acid.
FramycetinMycophenolic acid may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMycophenolic acid may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolic acid.
GentamicinMycophenolic acid may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.
HeparinMycophenolic acid may increase the anticoagulant activities of Heparin.
HirulogMycophenolic acid may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with HMPL-004.
HydralazineMycophenolic acid may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolic acid.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolic acid.
Hygromycin BMycophenolic acid may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.
IdarubicinMycophenolic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.
IndenololMycophenolic acid may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolic acid.
IndoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.
IsavuconazoniumThe serum concentration of Mycophenolic acid can be increased when it is combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Isoxicam.
KanamycinMycophenolic acid may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolic acid.
LabetalolMycophenolic acid may decrease the antihypertensive activities of Labetalol.
LansoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.
LeflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Leflunomide.
LepirudinMycophenolic acid may increase the anticoagulant activities of Lepirudin.
LevobunololMycophenolic acid may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mycophenolic acid.
LithiumThe serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.
LornoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.
LoxoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolic acid.
LumiracoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lumiracoxib.
MagaldrateMagaldrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Magnesium salicylate.
Magnesium SulfateThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolic acid.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mycophenolic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mycophenolic acid.
MesalazineMycophenolic acid may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mycophenolic acid.
MetamizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.
MeticillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Meticillin resulting in a loss in efficacy.
MetipranololMycophenolic acid may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.
MetoprololMycophenolic acid may decrease the antihypertensive activities of Metoprolol.
MetrizamideMycophenolic acid may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MetronidazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole.
MezlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Mezlocillin resulting in a loss in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolic acid.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolic acid.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolic acid.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Mycophenolic acid.
NadololMycophenolic acid may decrease the antihypertensive activities of Nadolol.
NadroparinMycophenolic acid may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Nafcillin resulting in a loss in efficacy.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mycophenolic acid.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Mycophenolic acid.
NatalizumabThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.
NCX 4016The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with NCX 4016.
NeomycinMycophenolic acid may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nepafenac.
NetilmicinMycophenolic acid may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.
OlsalazineMycophenolic acid may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mycophenolic acid.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mycophenolic acid.
OmeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Orgotein.
OtamixabanMycophenolic acid may increase the anticoagulant activities of Otamixaban.
OuabainOuabain may decrease the cardiotoxic activities of Mycophenolic acid.
OxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Oxacillin resulting in a loss in efficacy.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mycophenolic acid.
OxprenololMycophenolic acid may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.
PamidronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.
PantoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.
ParecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parecoxib.
ParomomycinMycophenolic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololMycophenolic acid may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateMycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mycophenolic acid.
PhenindioneMycophenolic acid may increase the anticoagulant activities of Phenindione.
PhenoxymethylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Phenoxymethylpenicillin resulting in a loss in efficacy.
PhenprocoumonMycophenolic acid may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mycophenolic acid.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.
PindololMycophenolic acid may decrease the antihypertensive activities of Pindolol.
PiperacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy.
PiretanideMycophenolic acid may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.
PivampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivampicillin resulting in a loss in efficacy.
PivmecillinamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivmecillinam resulting in a loss in efficacy.
PlicamycinMycophenolic acid may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolic acid.
PractololMycophenolic acid may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mycophenolic acid.
ProbenecidThe serum concentration of Mycophenolic acid can be increased when it is combined with Probenecid.
Procaine benzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Procaine benzylpenicillin resulting in a loss in efficacy.
PropacetamolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Propacetamol.
PropranololMycophenolic acid may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mycophenolic acid.
Protein CMycophenolic acid may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMycophenolic acid may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with PTC299.
PuromycinMycophenolic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolic acid.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolic acid.
RabeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rabies vaccine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolic acid.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolic acid.
ResveratrolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.
ReviparinMycophenolic acid may increase the anticoagulant activities of Reviparin.
RibostamycinMycophenolic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.
RivaroxabanMycophenolic acid may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Mycophenolic acid.
RoflumilastRoflumilast may increase the immunosuppressive activities of Mycophenolic acid.
SalicylamideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mycophenolic acid.
SalsalateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolic acid.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mycophenolic acid.
SeratrodastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seratrodast.
SevelamerThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sevelamer.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolic acid.
SotalolMycophenolic acid may decrease the antihypertensive activities of Sotalol.
SpectinomycinMycophenolic acid may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolic acid.
SpironolactoneMycophenolic acid may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with SRT501.
StreptomycinMycophenolic acid may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinMycophenolic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulbactamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sulbactam resulting in a loss in efficacy.
SulfasalazineMycophenolic acid may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mycophenolic acid.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolic acid.
SulodexideMycophenolic acid may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Mycophenolic acid.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolic acid.
TacrolimusMycophenolic acid may increase the nephrotoxic activities of Tacrolimus.
TAK-390MRThe serum concentration of Mycophenolic acid can be decreased when it is combined with TAK-390MR.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolic acid.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolic acid.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolic acid.
TenofovirThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolic acid.
TepoxalinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.
TicarcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ticarcillin resulting in a loss in efficacy.
TiludronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiludronate.
TimololMycophenolic acid may decrease the antihypertensive activities of Timolol.
TobramycinMycophenolic acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TofacitinibMycophenolic acid may increase the immunosuppressive activities of Tofacitinib.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolic acid.
TorasemideMycophenolic acid may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolic acid.
TranilastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tranilast.
TrastuzumabTrastuzumab may increase the neutropenic activities of Mycophenolic acid.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.
TriamtereneMycophenolic acid may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolic acid.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trisalicylate-choline.
ValaciclovirThe serum concentration of Mycophenolic acid can be increased when it is combined with Valaciclovir.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Mycophenolic acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mycophenolic acid.
WarfarinMycophenolic acid may increase the anticoagulant activities of Warfarin.
XimelagatranMycophenolic acid may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mycophenolic acid.
Zoledronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH2
Uniprot ID:
P12268
Molecular Weight:
55804.495 Da
References
  1. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M: An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004 Nov;36(9):2787-90. [PubMed:15621150 ]
  2. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, Hutchinson IV, Burckart GJ: A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics. 2007 Apr;17(4):283-90. [PubMed:17496727 ]
  3. Penuelas S, Noe V, Morales R, Ciudad CJ: Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH. Med Sci Monit. 2005 Jan;11(1):BR6-12. [PubMed:15614187 ]
  4. Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, Zaia JA, Yee JK: Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther. 2006 Aug;14(2):236-44. Epub 2006 May 2. [PubMed:16647299 ]
  5. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948 ]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH1
Uniprot ID:
P20839
Molecular Weight:
55405.365 Da
References
  1. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A7
Uniprot ID:
Q9HAW7
Molecular Weight:
59818.315 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Molecular Weight:
60750.215 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:27